Sarepta price target raised to $179 from $145 at Mizuho

Mizuho raised the firm’s price target on Sarepta to $179 from $145 and keeps a Buy rating on the shares. Following an investor call with an ex-FDA regulatory clinical expert, the firm has increased confidence in a potential broad label expansion for Elevidys. The expert believes there’s likely to be a label expansion based on her work on an analogous Lamzede case, the analyst tells investors in a research note. Mizuho now has higher confidence in a label expansion for Sarepta.